176 related articles for article (PubMed ID: 31492675)
21. Activation of EZH2 and SUZ12 Regulated by E2F1 Predicts the Disease Progression and Aggressive Characteristics of Bladder Cancer.
Lee SR; Roh YG; Kim SK; Lee JS; Seol SY; Lee HH; Kim WT; Kim WJ; Heo J; Cha HJ; Kang TH; Chung JW; Chu IS; Leem SH
Clin Cancer Res; 2015 Dec; 21(23):5391-403. PubMed ID: 26268246
[TBL] [Abstract][Full Text] [Related]
22. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.
Zhang J; Ding L; Holmfeldt L; Wu G; Heatley SL; Payne-Turner D; Easton J; Chen X; Wang J; Rusch M; Lu C; Chen SC; Wei L; Collins-Underwood JR; Ma J; Roberts KG; Pounds SB; Ulyanov A; Becksfort J; Gupta P; Huether R; Kriwacki RW; Parker M; McGoldrick DJ; Zhao D; Alford D; Espy S; Bobba KC; Song G; Pei D; Cheng C; Roberts S; Barbato MI; Campana D; Coustan-Smith E; Shurtleff SA; Raimondi SC; Kleppe M; Cools J; Shimano KA; Hermiston ML; Doulatov S; Eppert K; Laurenti E; Notta F; Dick JE; Basso G; Hunger SP; Loh ML; Devidas M; Wood B; Winter S; Dunsmore KP; Fulton RS; Fulton LL; Hong X; Harris CC; Dooling DJ; Ochoa K; Johnson KJ; Obenauer JC; Evans WE; Pui CH; Naeve CW; Ley TJ; Mardis ER; Wilson RK; Downing JR; Mullighan CG
Nature; 2012 Jan; 481(7380):157-63. PubMed ID: 22237106
[TBL] [Abstract][Full Text] [Related]
23. Inactivation of Eed impedes MLL-AF9-mediated leukemogenesis through Cdkn2a-dependent and Cdkn2a-independent mechanisms in a murine model.
Danis E; Yamauchi T; Echanique K; Haladyna J; Kalkur R; Riedel S; Zhu N; Xie H; Bernt KM; Orkin SH; Armstrong SA; Neff T
Exp Hematol; 2015 Nov; 43(11):930-935.e6. PubMed ID: 26118502
[TBL] [Abstract][Full Text] [Related]
24. FLT3 pathway is a potential therapeutic target for PRC2-mutated T-cell acute lymphoblastic leukemia.
Zhang J; Zhang Y; Zhang M; Liu C; Liu X; Yin J; Wu P; Chen X; Yang W; Zhang L; Guo Y; Zou Y; Chen Y; Cao Y; Cheng T; Zhu X
Blood; 2018 Dec; 132(23):2520-2524. PubMed ID: 30282797
[No Abstract] [Full Text] [Related]
25. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
26. Identification of a homozygous JAK3 V674A mutation caused by acquired uniparental disomy in a relapsed early T-cell precursor ALL patient.
Kawashima-Goto S; Imamura T; Seki M; Kato M; Yoshida K; Sugimoto A; Kaneda D; Fujiki A; Miyachi M; Nakatani T; Osone S; Ishida H; Taki T; Takita J; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Ogawa S; Hosoi H
Int J Hematol; 2015 Apr; 101(4):411-6. PubMed ID: 25430085
[TBL] [Abstract][Full Text] [Related]
27. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.
Li Y; Buijs-Gladdines JG; Canté-Barrett K; Stubbs AP; Vroegindeweij EM; Smits WK; van Marion R; Dinjens WN; Horstmann M; Kuiper RP; Buijsman RC; Zaman GJ; van der Spek PJ; Pieters R; Meijerink JP
PLoS Med; 2016 Dec; 13(12):e1002200. PubMed ID: 27997540
[TBL] [Abstract][Full Text] [Related]
28. The JAK3
Lahera A; Vela-Martín L; Fernández-Navarro P; Llamas P; López-Lorenzo JL; Cornago J; Santos J; Fernández-Piqueras J; Villa-Morales M
Mol Carcinog; 2024 Jan; 63(1):5-10. PubMed ID: 37712558
[TBL] [Abstract][Full Text] [Related]
29. PRC2-complex related dysfunction in overgrowth syndromes: A review of EZH2, EED, and SUZ12 and their syndromic phenotypes.
Cyrus S; Burkardt D; Weaver DD; Gibson WT
Am J Med Genet C Semin Med Genet; 2019 Dec; 181(4):519-531. PubMed ID: 31724824
[TBL] [Abstract][Full Text] [Related]
30. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex.
Cao R; Zhang Y
Mol Cell; 2004 Jul; 15(1):57-67. PubMed ID: 15225548
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
[TBL] [Abstract][Full Text] [Related]
32. PLK1 and HOTAIR Accelerate Proteasomal Degradation of SUZ12 and ZNF198 during Hepatitis B Virus-Induced Liver Carcinogenesis.
Zhang H; Diab A; Fan H; Mani SK; Hullinger R; Merle P; Andrisani O
Cancer Res; 2015 Jun; 75(11):2363-74. PubMed ID: 25855382
[TBL] [Abstract][Full Text] [Related]
33. The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications.
Kim SH; Yang WI; Min YH; Ko YH; Yoon SO
Tumour Biol; 2016 Feb; 37(2):2037-47. PubMed ID: 26337274
[TBL] [Abstract][Full Text] [Related]
34. Ezh2 loss propagates hypermethylation at T cell differentiation-regulating genes to promote leukemic transformation.
Wang C; Oshima M; Sato D; Matsui H; Kubota S; Aoyama K; Nakajima-Takagi Y; Koide S; Matsubayashi J; Mochizuki-Kashio M; Nakano-Yokomizo T; Bai J; Nagao T; Kanai A; Iwama A; Sashida G
J Clin Invest; 2018 Aug; 128(9):3872-3886. PubMed ID: 30080177
[TBL] [Abstract][Full Text] [Related]
35. Anti-leukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells.
Valiulienė G; Stirblytė I; Jasnauskaitė M; Borutinskaitė V; Navakauskienė R
Eur J Pharmacol; 2017 Mar; 799():143-153. PubMed ID: 28192098
[TBL] [Abstract][Full Text] [Related]
36. Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
Degryse S; de Bock CE; Demeyer S; Govaerts I; Bornschein S; Verbeke D; Jacobs K; Binos S; Skerrett-Byrne DA; Murray HC; Verrills NM; Van Vlierberghe P; Cools J; Dun MD
Leukemia; 2018 Mar; 32(3):788-800. PubMed ID: 28852199
[TBL] [Abstract][Full Text] [Related]
37. The polycomb group protein SUZ12 regulates histone H3 lysine 9 methylation and HP1 alpha distribution.
de la Cruz CC; Kirmizis A; Simon MD; Isono K; Koseki H; Panning B
Chromosome Res; 2007; 15(3):299-314. PubMed ID: 17406994
[TBL] [Abstract][Full Text] [Related]
38. Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity.
Pasini D; Bracken AP; Jensen MR; Lazzerini Denchi E; Helin K
EMBO J; 2004 Oct; 23(20):4061-71. PubMed ID: 15385962
[TBL] [Abstract][Full Text] [Related]
39. JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia.
Uckun FM; Pitt J; Qazi S
Expert Rev Anticancer Ther; 2011 Jan; 11(1):37-48. PubMed ID: 21070101
[TBL] [Abstract][Full Text] [Related]
40. EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma.
Yan J; Li B; Lin B; Lee PT; Chung TH; Tan J; Bi C; Lee XT; Selvarajan V; Ng SB; Yang H; Yu Q; Chng WJ
Blood; 2016 Aug; 128(7):948-58. PubMed ID: 27297789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
